Top Suppliers:I want be here


  • DC Chemicals Limited
  • China
  • Product Name: R-1479
  • Price: $400.0/10mg $1200.0/50mg $1680.0/100mg
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

478182-28-4

478182-28-4 structure
478182-28-4 structure
  • Name: R-1479
  • Chemical Name: 4-amino-1-[(2R,3R,4S,5R)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
  • CAS Number: 478182-28-4
  • Molecular Formula: C9H12N6O5
  • Molecular Weight: 284.229
  • Catalog: Chemical reagent Organic reagent Azide
  • Create Date: 2018-08-26 18:38:15
  • Modify Date: 2024-01-09 00:15:03
  • R-1479 is a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM).

Name 4-amino-1-[(2R,3R,4S,5R)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
Synonyms 4-amino-1-[(2R,3R,4S,5R)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one (non-preferred name)
R-1479||4'-Azidocytidine|R1479
CS-0362
4'-azidocytidine
4'azidocytidine
R1479
4-Amino-1-[(2R,3R,4S,5R)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-2(1H)-pyrimidinone
R-1479
Description R-1479 is a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM).
Related Catalog
Target

IC50: 1.28 μM (HCV replication)[1]

In Vitro R-1479 (R1479) inhibits HCV RNA replication with a mean IC50 value of 1.28 μM when measured as dose-dependent reduction of Renillaluciferase activity after a 72 h incubation of proliferating replicon cells. R-1479 shows no effect on cell viability or proliferation of HCV replicon or Huh-7 cells at concentrations up to 2 mM[1]. The most potent and non-cytotoxic derivative is R-1479 with an IC50 of 1.28 μM in the HCV replicon system. The triphosphate of R-1479 is prepared and shown to be an inhibitor of RNA synthesis mediated by NS5B (IC50=320 nM), the RNA polymerase encoded by HCV. R-1479 displays good activity in the replicon assay with no measurable cytotoxic or cytostatic effect[2].
Kinase Assay The membrane-associated, native HCV replicase complex is isolated from 2209-23 HCV replicon cells and a derived cell line carrying HCV replicon RNA with a S282T mutation in the NS5B coding sequence. The in vitro replicase assay contain 10 μL of cytoplasmic membrane fraction, 50 mM HEPES (pH 7.5), 10 mM KCl, 10 mM dithiothreitol, 5 mM MgCl2, 20 μg/mL actinomycin D, 1 mM ATP, 1 mM GTP, 1 mM UTP, 30 μCi of [α-33P]CTP (3000 Ci/mmol, 10 mCi/mL), 1 unit/μL SUPERase•In, 10 mM creatine phosphate, and 200 μg/mL creatine phosphokinase in a final volume of 25 μL. Inhibition by nucleotide analogs is determined[1].
Cell Assay The effect of R-1479 on the incorporation of tritiated thymidine into cellular DNA is measured using the [3H]thymidine incorporation scintillation proximity assay system. MTT and WST-1 assay systems are used to measure cell viability. The ATP bioluminescence assay kit HSII is used to measure intracellular ATP levels[1].
References

[1]. Klumpp K, et al. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem. 2006 Feb 17;281(7):3793-9.

[2]. Smith DB, et al. Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg Med Chem Lett. 2007 May 1;17(9):2570-6.

Molecular Formula C9H12N6O5
Molecular Weight 284.229
Exact Mass 284.086914
PSA 181.57000
LogP -0.20
Storage condition -20°C

~%

478182-28-4 structure

478182-28-4

Literature: Smith, David B.; Martin, Joseph A.; Klumpp, Klaus; Baker, Stewart J.; Blomgren, Peter A.; Devos, Rene; Granycome, Caroline; Hang, Julie; Hobbs, Christopher J.; Jiang, Wen-Rong; Laxton, Carl; Pogam, Sophie Le; Leveque, Vincent; Ma, Han; Maile, Graham; Merrett, John H.; Pichota, Arkadius; Sarma, Keshab; Smith, Mark; Swallow, Steven; Symons, Julian; Vesey, David; Najera, Isabel; Cammack, Nick Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 9 p. 2570 - 2576

~%

478182-28-4 structure

478182-28-4

Literature: Smith, David B.; Martin, Joseph A.; Klumpp, Klaus; Baker, Stewart J.; Blomgren, Peter A.; Devos, Rene; Granycome, Caroline; Hang, Julie; Hobbs, Christopher J.; Jiang, Wen-Rong; Laxton, Carl; Pogam, Sophie Le; Leveque, Vincent; Ma, Han; Maile, Graham; Merrett, John H.; Pichota, Arkadius; Sarma, Keshab; Smith, Mark; Swallow, Steven; Symons, Julian; Vesey, David; Najera, Isabel; Cammack, Nick Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 9 p. 2570 - 2576

~%

478182-28-4 structure

478182-28-4

Literature: Smith, David B.; Martin, Joseph A.; Klumpp, Klaus; Baker, Stewart J.; Blomgren, Peter A.; Devos, Rene; Granycome, Caroline; Hang, Julie; Hobbs, Christopher J.; Jiang, Wen-Rong; Laxton, Carl; Pogam, Sophie Le; Leveque, Vincent; Ma, Han; Maile, Graham; Merrett, John H.; Pichota, Arkadius; Sarma, Keshab; Smith, Mark; Swallow, Steven; Symons, Julian; Vesey, David; Najera, Isabel; Cammack, Nick Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 9 p. 2570 - 2576

~%

478182-28-4 structure

478182-28-4

Literature: Smith, David B.; Martin, Joseph A.; Klumpp, Klaus; Baker, Stewart J.; Blomgren, Peter A.; Devos, Rene; Granycome, Caroline; Hang, Julie; Hobbs, Christopher J.; Jiang, Wen-Rong; Laxton, Carl; Pogam, Sophie Le; Leveque, Vincent; Ma, Han; Maile, Graham; Merrett, John H.; Pichota, Arkadius; Sarma, Keshab; Smith, Mark; Swallow, Steven; Symons, Julian; Vesey, David; Najera, Isabel; Cammack, Nick Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 9 p. 2570 - 2576

~%

478182-28-4 structure

478182-28-4

Literature: Smith, David B.; Martin, Joseph A.; Klumpp, Klaus; Baker, Stewart J.; Blomgren, Peter A.; Devos, Rene; Granycome, Caroline; Hang, Julie; Hobbs, Christopher J.; Jiang, Wen-Rong; Laxton, Carl; Pogam, Sophie Le; Leveque, Vincent; Ma, Han; Maile, Graham; Merrett, John H.; Pichota, Arkadius; Sarma, Keshab; Smith, Mark; Swallow, Steven; Symons, Julian; Vesey, David; Najera, Isabel; Cammack, Nick Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 9 p. 2570 - 2576

~%

478182-28-4 structure

478182-28-4

Literature: Smith, David B.; Martin, Joseph A.; Klumpp, Klaus; Baker, Stewart J.; Blomgren, Peter A.; Devos, Rene; Granycome, Caroline; Hang, Julie; Hobbs, Christopher J.; Jiang, Wen-Rong; Laxton, Carl; Pogam, Sophie Le; Leveque, Vincent; Ma, Han; Maile, Graham; Merrett, John H.; Pichota, Arkadius; Sarma, Keshab; Smith, Mark; Swallow, Steven; Symons, Julian; Vesey, David; Najera, Isabel; Cammack, Nick Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 9 p. 2570 - 2576

~%

478182-28-4 structure

478182-28-4

Literature: Smith, David B.; Martin, Joseph A.; Klumpp, Klaus; Baker, Stewart J.; Blomgren, Peter A.; Devos, Rene; Granycome, Caroline; Hang, Julie; Hobbs, Christopher J.; Jiang, Wen-Rong; Laxton, Carl; Pogam, Sophie Le; Leveque, Vincent; Ma, Han; Maile, Graham; Merrett, John H.; Pichota, Arkadius; Sarma, Keshab; Smith, Mark; Swallow, Steven; Symons, Julian; Vesey, David; Najera, Isabel; Cammack, Nick Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 9 p. 2570 - 2576
Precursor  3

DownStream  0